Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases have announced that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to USD 3.1 billion.

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialise abelacimab, a novel Factor XI inhibitor that originated at Novartis. 

Abelacimab is currently in Phase 3 clinical development for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.

Anthos shareholders will receive up to USD 3.1 billion in total deal value, including an upfront payment of USD 925 million, and payments in the event certain regulatory and commercial milestones are achieved.

Goldman Sachs & Co. LLC acted as the lead financial advisor to Anthos. Morgan Stanley & Co. LLC also served as a financial advisor, and Goodwin Procter LLP served as legal advisor to Anthos.

Blackstone Life Sciences (BXLS) is a private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has USD 12 billion in assets under management.